NASDAQ · CBUS
Healthcare · Biotechnology
$1.90
Up+$0.01 (+0.53%)
Updated Aug 14, 2026, 5:16 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
CBUS closed at $1.90 after 21 trading sessions, up 4.97% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $1.93 | $2.07 | $1.8974 | $1.90 | 245.31K |
| Aug 12, 2026 | $1.93 | $1.99 | $1.84 | $1.89 | 90.94K |
| Aug 11, 2026 | $1.93 | $2.06 | $1.86 | $1.90 | 157.13K |
| Aug 10, 2026 | $1.83 | $1.97 | $1.80 | $1.91 | 215.21K |
| Aug 7, 2026 | $1.89 | $1.89 | $1.75 | $1.81 | 163.62K |
| Aug 6, 2026 | $1.95 | $1.99 | $1.79 | $1.87 | 105.75K |
| Aug 5, 2026 | $1.93 | $1.99 | $1.88 | $1.93 | 167.39K |
| Aug 4, 2026 | $1.91 | $1.99 | $1.87 | $1.92 | 138.81K |
| Aug 3, 2026 | $1.93 | $1.99 | $1.80 | $1.89 | 168.98K |
| Jul 31, 2026 | $1.95 | $1.96 | $1.7761 | $1.93 | 141.62K |
| Jul 30, 2026 | $1.93 | $2.04 | $1.86 | $1.93 | 190.83K |
| Jul 29, 2026 | $1.95 | $2.02 | $1.87 | $1.94 | 202.25K |
| Jul 28, 2026 | $1.82 | $1.95 | $1.70 | $1.94 | 151.44K |
| Jul 27, 2026 | $1.72 | $1.82 | $1.62 | $1.81 | 173.38K |
| Jul 24, 2026 | $1.81 | $1.81 | $1.675 | $1.70 | 94.7K |
| Jul 23, 2026 | $1.75 | $1.82 | $1.7001 | $1.78 | 64.35K |
| Jul 22, 2026 | $1.85 | $1.88 | $1.73 | $1.79 | 130.2K |
| Jul 21, 2026 | $1.79 | $1.90 | $1.76 | $1.86 | 213.19K |
| Jul 20, 2026 | $1.78 | $1.84 | $1.73 | $1.76 | 119.96K |
| Jul 17, 2026 | $1.79 | $1.83 | $1.72 | $1.79 | 206.22K |
| Jul 16, 2026 | $2.02 | $2.07 | $1.81 | $1.81 | 351.04K |
The latest Smart Investors Daily articles mentioning CBUS.
CBUS research
Company profile and research snapshot.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 25, 2026 | Jefferies | Hold | — |
| Dec 8, 2025 | Canaccord Genuity | Buy | — |
| May 12, 2025 | Canaccord Genuity | Buy | — |
| Mar 21, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 22, 2025 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Benzinga · Feb 6, 2026
Cibus to utilize proprietary Rapid Trait Development System™ to enable development of durable resistance to Light Leaf Spot disease, which has caused estimated yield losses of up to £300m in recent yearsSAN DIEGO,
Benzinga · Jan 29, 2026
Benzinga · Jan 29, 2026
The Company has also granted the underwriter a 30-day option to purchase up to an additional 1,999,999 shares of Class A Common Stock to cover over-allotments, if any. All shares of Class A Common Stock to be sold in the
Benzinga · Jan 28, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CBUS.
